NCT02808767

Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,226 (actual)
• Sponsor: Faculty Hospital Kralovske Vinohrady · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the efficacy of Prasugrel and Ticagrelor in the treatment of acute myocardial infarction.

Detailed description

Study objectives: 1. Compare the efficacy and safety of prasugrel and ticagrelor in acute myocardial infarction treated with emergent PCI. 2. Assess the safety of switching to clopidogrel after remission of the acute phase of MI in patients for whom economic barriers do not allow to continue treatment with prasugrel or ticagrelor. All randomized patients with acute myocardial infarction have been treated with standard therapeutic procedures in accordance with the guidelines of European Society of Cardiology (ESC). Participation of patients in the study is not connected to any deviations from the ESC guidelines recommendations.

Conditions

• Myocardial Infarction
• Angioplasty, Balloon, Coronary
• Platelet Aggregation Inhibitors

Interventions

Type	Name	Description
DRUG	Prasugrel	Prasugrel 60 mg loading dose and 10mg/5mg once daily maintenance dose
DRUG	Ticagrelor	Ticagrelor 180 mg loading dose and 90 mg twice daily maintenance dose

Timeline

• Start date: 2013-01-01
• Primary completion: 2016-05-01
• Completion: 2017-05-01
• First posted: 2016-06-22
• Last updated: 2017-08-11

Locations

1 site across 1 country: Czechia